Acetylon Pharmaceuticals Announces Addition of Catherine A. Wheeler MD as Vice President Clinical Development

Published: Dec 12, 2011

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced the appointment of Catherine A. Wheeler, MD, as Vice President, Clinical Development. She joins Acetylon following a distinguished career in oncology pharmaceuticals development, including senior clinical development roles with Roche and AstraZeneca. Dr. Wheeler will have responsibility for all clinical development functions of the Company, including current and future clinical trials of Acetylon’s HDAC6 selective drug candidate, ACY-1215, in multiple myeloma as well as other potential hematologic and solid tumor disease indications. She will also lead the clinical development of future drug candidates in inflammatory and neurodegenerative diseases.

Back to news